ARI2485

Clinical Trial Title The Comprehensive Analysis of PIK3CA Mutations in Breast Cancer
Trial Status Open to Enrollment
Start Date 07/21/2026
Location All Hospitals
Trial Type Cancer - Adult Oncology
Specific Condition Breast Cancer
Description
Eligibility Criteria

Inclusion Criteria

  • Subject must self-report negative for HIV, or Hepatitis A, B, or C.
  • Subjects must be diagnosed by a certified physician and histologically confirmed to have invasive disease. The subject may have a pending diagnosis at time of surgery, but resultant histological diagnosis rendered by a certified pathologist must confirm the cancer subtype.
  • Subject must have active disease at time of collection.
  • Subjects may be treated or untreated. If treated, treatment agent and doses must be known.

Exclusion Criteria

  • Subjects with more than one present diagnoses of cancer.

Please contact Legacy Oncology Research for additional study inclusion/exclusion information.

IRB Number Central IRB
Notes
Principal Investigator Nathalie Johnson, MD
Contact Name Oncology Clinical Research
Contact Phone 503-413-8199
Contact Fax 503-413-6920
Contact E-Mail oncologyresearch@lhs.org